18-31074850-C-T
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4BP6
The NM_024422.6(DSC2):c.1721G>A(p.Ser574Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000874 in 1,613,806 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_024422.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DSC2 | NM_024422.6 | c.1721G>A | p.Ser574Asn | missense_variant | 12/16 | ENST00000280904.11 | NP_077740.1 | |
DSC2 | NM_004949.5 | c.1721G>A | p.Ser574Asn | missense_variant | 12/17 | NP_004940.1 | ||
DSC2 | NM_001406506.1 | c.1292G>A | p.Ser431Asn | missense_variant | 12/16 | NP_001393435.1 | ||
DSC2 | NM_001406507.1 | c.1292G>A | p.Ser431Asn | missense_variant | 12/17 | NP_001393436.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DSC2 | ENST00000280904.11 | c.1721G>A | p.Ser574Asn | missense_variant | 12/16 | 1 | NM_024422.6 | ENSP00000280904 | P1 | |
DSC2 | ENST00000251081.8 | c.1721G>A | p.Ser574Asn | missense_variant | 12/17 | 1 | ENSP00000251081 | |||
DSC2 | ENST00000648081.1 | c.1292G>A | p.Ser431Asn | missense_variant | 13/17 | ENSP00000497441 | ||||
DSC2 | ENST00000682357.1 | c.1292G>A | p.Ser431Asn | missense_variant | 12/16 | ENSP00000507826 |
Frequencies
GnomAD3 genomes AF: 0.0000921 AC: 14AN: 152048Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000637 AC: 16AN: 251034Hom.: 0 AF XY: 0.0000369 AC XY: 5AN XY: 135682
GnomAD4 exome AF: 0.0000869 AC: 127AN: 1461758Hom.: 0 Cov.: 32 AF XY: 0.0000743 AC XY: 54AN XY: 727164
GnomAD4 genome AF: 0.0000921 AC: 14AN: 152048Hom.: 0 Cov.: 32 AF XY: 0.0000673 AC XY: 5AN XY: 74260
ClinVar
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jul 24, 2020 | The DSC2 c.1721G>A; p.Ser574Asn variant (rs150318400) is reported in the literature in an individual affected with arrhythmogenic right ventricular cardiomyopathy (ARVC) and in the parent of a child with sudden unexpected death and suspected ARVC (Quarta 2011, van der Werf 2010). This variant is found in the non-Finnish European population with an overall allele frequency of 0.01% (16/128894 alleles) in the Genome Aggregation Database. The serine at codon 574 is weakly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is tolerated. However, given the lack of clinical and functional data, the significance of the p.Ser574Asn variant is uncertain at this time. References: Quarta et al. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation. 2011;123(23):2701-2709. van der Werf C et al. Diagnostic yield in sudden unexplained death and aborted cardiac arrest in the young: the experience of a tertiary referral center in The Netherlands. Heart Rhythm. 2010;7(10):1383-1389. - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Sep 10, 2021 | Reported in association with arrhythmogenic right ventricular dysplasia (ARVC) and dilated cardiomyopathy (DCM) (Quarta et al., 2011; van Lint et al., 2019; Verdonschot et al., 2020), as well as in a woman with "probable" ARVC whose child was a victim of sudden unexplained death (van der Werf et al., 2010); however, additional clinical and segregation data were not provided; In silico analysis supports that this missense variant does not alter protein structure/function; Reported in ClinVar (ClinVar Variant ID# 178018; Landrum et al., 2016); This variant is associated with the following publications: (PMID: 23299917, 20646679, 21606390, 31402444, 30847666, 32880476) - |
not specified Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | May 01, 2014 | The Ser574Asn variant in DSC2 has been reported in 1 individual with ARVC (Quart a 2011). It has also been identified in 4/8600 European American chromosomes by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/; dbSNP rs1 50318400). Serine (Ser) at position 574 is not conserved evolution, raising the possibility that a change at this position may be tolerated. In summary, the cli nical significance of the Ser574Asn variant is uncertain. - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 21, 2021 | Variant summary: DSC2 c.1721G>A (p.Ser574Asn) results in a conservative amino acid change located in the Cadherin-like domain (IPR002126) of the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 6.4e-05 in 251034 control chromosomes, predominantly at a frequency of 0.00014 within the Non-Finnish European subpopulation in the gnomAD database. The observed variant frequency within Non-Finnish European control individuals in the gnomAD database is approximately 5.6- fold the estimated maximal expected allele frequency for a pathogenic variant in DSC2 causing Cardiomyopathy phenotype (2.5e-05), suggesting that the variant is a benign polymorphism found primarily in populations of Non-Finnish European origin. c.1721G>A has been reported in the literature in individuals affected with Cardiomyopathy (e.g. van der Werf_2010, van Lint_2019, Verdonschot_2020). These reports do not provide unequivocal conclusions about association of the variant with Cardiomyopathy. Co-occurrence with another pathogenic variant has been reported in an internal sample (KCNQ1 c.1781G>A, p.R594Q), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories cited the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as likely benign. - |
Arrhythmogenic right ventricular dysplasia 11 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 28, 2024 | This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 574 of the DSC2 protein (p.Ser574Asn). This variant is present in population databases (rs150318400, gnomAD 0.01%). This missense change has been observed in individual(s) with arrhythmogenic right ventricular dyplasia/cardiomyopathy, dilated cardiomyopathy, and/or unspecified cardiomyopathy (PMID: 20646679, 21606390, 30847666, 32880476). ClinVar contains an entry for this variant (Variation ID: 178018). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt DSC2 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Dec 02, 2022 | This missense variant replaces serine with asparagine at codon 574 of the DSC2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with arrhythmogenic right ventricular cardiomyopathy (PMID: 21606390). This variant has also been identified in 17/282410 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Familial isolated arrhythmogenic right ventricular dysplasia Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Dec 15, 2023 | This missense variant replaces serine with asparagine at codon 574 of the DSC2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individuals affected with arrhythmogenic right ventricular cardiomyopathy (PMID: 21606390). This variant has also been identified in 17/282410 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 11, 2021 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at